## Julien Calderaro

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4966833/julien-calderaro-publications-by-year.pdf

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72 6,381 30 78 g-index

78 8,488 9.5 5.88 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
72	Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	6
71	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study <i>Lancet Oncology, The,</i> <b>2022</b> , 23, 161-171	21.7	1
70	Interleukin-17 programs liver progenitor cell transformation into cancer stem cells through miR-122 downregulation with increased risk of primary liver cancer initiation <i>International Journal of Biological Sciences</i> , <b>2022</b> , 18, 1944-1960	11.2	O
69	Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma <i>Journal of Hepatology</i> , <b>2022</b> , 76, 1348-1361	13.4	3
68	Immune profiling of combined hepatocellular-cholangiocarcinoma reveals distinct subtypes and activation of gene signatures predictive of response to immunotherapy. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	3
67	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	3
66	Pathologic and molecular features of hepatocellular carcinoma: An update. <i>World Journal of Hepatology</i> , <b>2021</b> , 13, 393-410	3.4	4
65	Combined hepatocellular-cholangiocarcinoma: An update. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1212-1224	13.4	24
64	Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers. <i>Gut</i> , <b>2021</b> , 70, 118	8 <b>3</b> -9. <b>1</b> 9	3 <sub>24</sub>
63	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1155-1166	13.4	11
62	REPLY. <i>Hepatology</i> , <b>2021</b> , 73, 2078-2079	11.2	1
61	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. <i>Gut</i> , <b>2021</b> ,	19.2	29
60	Identification of an EML4-ALK rearrangement in an intrahepatic cholangiocarcinoma. <i>Pathology International</i> , <b>2021</b> , 71, 630-632	1.8	1
59	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. <i>Hepatology</i> , <b>2021</b> , 74, 816-834	11.2	7
58	Artificial intelligence for solid tumour diagnosis in digital pathology. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 4291-4315	8.6	2
57	HistosEninaire « Pathologie tumorale hpatique » : prEtests. <i>Annales De Pathologie</i> , <b>2021</b> , 41, 430-433	0.3	
56	Primary leiomyosarcoma of the liver: Two new cases and a systematic review. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , <b>2020</b> , 24, 63-67	1.5	5

## (2019-2020)

55	Development of AI-based pathology biomarkers in gastrointestinal and liver cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 591-592	24.2	23
54	Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides. <i>Hepatology</i> , <b>2020</b> , 72, 2000-2013	11.2	59
53	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4381-4389	12.9	21
52	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 924-936	13.4	18
51	A deep learning model to predict RNA-Seq expression of tumours from whole slide images. <i>Nature Communications</i> , <b>2020</b> , 11, 3877	17.4	84
50	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , <b>2020</b> , 71, 164-182	11.2	62
49	Polyploidy spectrum: a new marker in HCC classification. <i>Gut</i> , <b>2020</b> , 69, 355-364	19.2	34
48	Adeno-associated virus in the liver: natural history and consequences in tumour development. <i>Gut</i> , <b>2020</b> , 69, 737-747	19.2	36
47	Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy. <i>Liver International</i> , <b>2020</b> , 40, 74-82	7.9	9
46	Multiphase Liver MRI for Identifying the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma. <i>Radiology</i> , <b>2020</b> , 295, 562-571	20.5	30
45	Molecular and histological correlations in liver cancer. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 616-630	13.4	131
44	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , <b>2019</b> , 19, 307	-3,25;	397
43	A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. <i>Hepatology</i> , <b>2019</b> , 70, 231-240	11.2	51
42	Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping. <i>European Radiology</i> , <b>2019</b> , 29, 3791-3801	8	14
41	germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. <i>Oncolmmunology</i> , <b>2019</b> , 8, e1583547	7.2	16
40	ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5859-5865	12.9	26
39	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. <i>Gastroenterology</i> , <b>2019</b> , 157, 760-776	13.3	77
38	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 58-65	13.4	86

37	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 533-544	7.5	43
36	Interleukins-17 and 27 promote liver regeneration by sequentially inducing progenitor cell expansion and differentiation. <i>Hepatology Communications</i> , <b>2018</b> , 2, 329-343	6	12
35	Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 336-344	13.4	28
34	Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. <i>Hepatology</i> , <b>2018</b> , 68, 949-963	11.2	60
33	Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. <i>Hepatology</i> , <b>2018</b> , 68, 103-112	11.2	83
32	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. <i>Hepatology</i> , <b>2018</b> , 68, 964-976	11.2	25
31	Polycystic kidney features of the renal pathology in glycogen storage disease type I: possible evolution to renal neoplasia. <i>Journal of Inherited Metabolic Disease</i> , <b>2018</b> , 41, 955-963	5.4	10
30	Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin. <i>Blood</i> , <b>2018</b> , 132, 4597-4597	2.2	Ο
29	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. <i>Nature Communications</i> , <b>2018</b> , 9, 5235	17.4	73
28	Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 1074-1087	13.4	22
27	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 727-738	13.4	302
26	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 734-742	13.4	25
25	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , <b>2017</b> , 152, 880-894.e6	13.3	198
24	Impact of hepatobiliary phase liver MRI versus Contrast-Enhanced Ultrasound after an inconclusive extracellular gadolinium-based contrast-enhanced MRI for the diagnosis of benign hepatocellular tumors. <i>Abdominal Radiology</i> , <b>2017</b> , 42, 825-832	3	8
23	Benign Tumors, Nodules, and Cystic Diseases of the Liver <b>2017</b> , 947-976		
22	Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. <i>Hepatology</i> , <b>2016</b> , 64, 2038-2046	11.2	242
21	Solitary splenic metastasis from nasopharyngeal carcinoma: a case report and systematic review of the literature. <i>World Journal of Surgical Oncology</i> , <b>2016</b> , 14, 184	3.4	14
20	Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and (18)F-FDG PET/CT in patients on waiting-list for liver transplantation. <i>Cancer Imaging</i> , <b>2016</b> , 16, 4	5.6	19

## (2011-2016)

19	Genotype-phenotype correlation of CTNNB1 mutations reveals different Etatenin activity associated with liver tumor progression. <i>Hepatology</i> , <b>2016</b> , 64, 2047-2061	11.2	144
18	An Unusual Cause of Cholecystitis. <i>Gastroenterology</i> , <b>2016</b> , 150, e3-e4	13.3	3
17	Ultrasonography of gallbladder abnormalities due to schistosomiasis. <i>Parasitology Research</i> , <b>2016</b> , 115, 2917-24	2.4	16
16	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , <b>2015</b> , 47, 505-511	36.3	956
15	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. <i>Nature Genetics</i> , <b>2015</b> , 47, 1187-93	36.3	290
14	Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1173-80	13.4	65
13	Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. <i>Gut</i> , <b>2015</b> , 64, 820-9	19.2	101
12	BRAF V600E mutational status in bile duct adenomas and hamartomas. <i>Histopathology</i> , <b>2015</b> , 67, 562-7	7.3	16
11	Bile duct adenoma should not be designated as a reactive process. <i>Pathology International</i> , <b>2015</b> , 65, 338	1.8	2
10	Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. <i>Oncotarget</i> , <b>2015</b> , 6, 10102-15	3.3	43
9	Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. <i>Cancer Cell</i> , <b>2014</b> , 25, 428-41	24.3	198
8	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. <i>Hepatology</i> , <b>2014</b> , 60, 1983-92	11.2	202
7	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. <i>Nature Communications</i> , <b>2013</b> , 4, 2218	17.4	407
6	ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 1264-70	13.4	31
5	A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. <i>Gastroenterology</i> , <b>2013</b> , 145, 176-187	13.3	254
4	Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. <i>OncoImmunology</i> , <b>2013</b> , 2, e27090	7.2	30
3	Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. <i>Nature Genetics</i> , <b>2012</b> , 44, 694-8	36.3	996
2	Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. <i>Hepatology</i> , <b>2011</b> , 53, 1182-91	11.2	157

1 Transcriptomic learning for digital pathology

4